Skip Nav Destination
1-2 of 2
Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD
Blood (2019) 134 (Supplement_1): 736.
Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial
Jorge E. Cortes, MD, Samer K. Khaled, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Siddhartha Ganguly, MD, Nigel H. Russell, Alwin Kramer, MD, Herve Dombret, MD, Donna Hogge, Brian A. Jonas, MD PhD, Anskar Y.-H. Leung, MD PhD, Priyanka Mehta, Pau Montesinos, MD PhD, Markus P. Radsak, MD, Simona Sica, MD, Meena Arunachalam, Melissa Holmes, Ken Kobayashi, MD, Ruth Namuyinga, MD MPH, Nanxiang Ge, Antoine Yver, MD, Yufen Zhang, Mark J. Levis, MD
Blood (2018) 132 (Supplement 1): 563.